JPRN-UMIN000034923招募中未知
Detection of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer using circulating tumor DNA - Circulating tumor DNA in RAS-wildtype colorectal cancer
Kanazawa University Graduate School of Medicine, Department of Cardiovascular and Internal Medicine0 个研究点目标入组 50 人开始时间: 2018年11月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients diagnosed as double primary cancer 2. Patients with hereditary cancer syndrome
研究者
相似试验
招募中
不适用
A study of the resistance mechanism of EGFR-TKI in EGFR gene mutation positive non-small cell lung cancerJPRN-UMIN000031013Kyoto prefectural University of Medicine35
招募中
不适用
Analysis of response and acquired resistance to EGFR-TKI by multiple circulating tumor DNA with cancer-specific gene mutationson-small cell lung cancerJPRN-UMIN000028990Osaka International Cancer Institute80
已完成
4 期
Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).Advanced NSCLCNCT05219162AstraZeneca182
进行中（未招募）
1 期
Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR)inoperable, untreated, wild type RAS (wt KRAS/wtNRAS), metastatic colorectal cancer (mCRC)EUCTR2018-001210-15-CZMasarykuv onkologický ústav375
进行中（未招募）
4 期
Can extra tests on cancer samples identify more patients with bowel/colon cancer who should be treated with drugs called anti-EGFR agents?CancerISRCTN11061442niversity of Leeds440